Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Kymera Therapeutics (NASDAQ:KYMR) released its earnings results on Thursday. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20), FiscalAI reports. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the previous year, the company posted ($0.88) earnings per share. The firm’s quarterly revenue was down 60.8% on a year-over-year basis.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• Kymera’s first‑in‑class oral STAT6 degrader KT‑621 showed robust STAT6 degradation, strong type‑2 biomarker suppression and dupilumab‑like clinical signals in Phase 1/1b, and is now in Phase 2b trials for atopic dermatitis (enrollment expected complete end‑2026; topline mid‑2027) and asthma (first patient dosed; data expected late‑2027).
• Kymera has initiated dosing of its oral IRF5 degrader KT‑579 in a Phase 1 SAD/MAD healthy volunteer study after IND clearance and expects first‑in‑human data in H2 2026, with a planned lupus proof‑of‑concept to follow.
• The company raised nearly $1.0 billion in 2025 and finished the year with a cash balance of $1.6 billion, which management says provides a runway into 2029 to complete KT‑621 Phase 2b trials and advance KT‑579 and other programs.
• Kymera continues partnered development with Gilead (CDK2 molecular glue) and Sanofi (IRAK4 KT‑485), with potential milestone payments (Gilead up to ~$750M; Sanofi program structure could approach ~$1B) that aren’t included in current cash guidance.
• Q4 R&D expense was $83.8 million (cash R&D ~$76.2M), a 16% increase vs. Q3, highlighting rising development spend that will drive ongoing cash burn despite the stated runway.

Kymera Therapeutics Stock Down 5.1%

Shares of KYMR traded down $4.88 during mid-day trading on Friday, hitting $90.15. The company had a trading volume of 350,006 shares, compared to its average volume of 775,806. The business’s 50-day simple moving average is $78.37 and its 200-day simple moving average is $64.89. Kymera Therapeutics has a 1-year low of $19.44 and a 1-year high of $103.00. The stock has a market cap of $6.49 billion, a PE ratio of -25.06 and a beta of 2.21.

Insider Activity

In related news, Director Bros. Advisors Lp Baker purchased 2,005,813 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average price of $86.00 per share, with a total value of $172,499,918.00. Following the completion of the purchase, the director directly owned 7,955,916 shares in the company, valued at approximately $684,208,776. This trade represents a 33.71% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.76, for a total transaction of $448,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 450,895 shares of company stock valued at $40,486,151 in the last ninety days. 16.01% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. lifted its stake in shares of Kymera Therapeutics by 3.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock valued at $49,001,000 after purchasing an additional 18,524 shares in the last quarter. Invesco Ltd. lifted its position in Kymera Therapeutics by 46.3% during the fourth quarter. Invesco Ltd. now owns 116,747 shares of the company’s stock valued at $9,084,000 after buying an additional 36,940 shares in the last quarter. Vident Advisory LLC grew its stake in Kymera Therapeutics by 6.5% during the fourth quarter. Vident Advisory LLC now owns 7,581 shares of the company’s stock worth $590,000 after buying an additional 465 shares during the period. Mackenzie Financial Corp purchased a new stake in Kymera Therapeutics during the fourth quarter worth approximately $270,000. Finally, XTX Topco Ltd acquired a new stake in shares of Kymera Therapeutics in the fourth quarter worth $1,879,000.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Large cash raise and program progress extend runway — Kymera reported a $1.6B cash infusion and highlighted progress with KT‑621, which management says materially extends the company’s development runway into 2029 and supports continued investment in its degrader pipeline. Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
• Positive Sentiment: Analyst bull case: Piper Sandler raised its price target to $140 (overweight), signaling continued analyst conviction into the pipeline and giving upside vs. current levels. Piper Sandler price target raise
• Positive Sentiment: Consensus broker view remains favorable — several brokerages maintain Buy/Overweight ratings and the street average recommendation is around “Buy,” which can support interest from institutional investors. Average Recommendation of Buy
• Neutral Sentiment: KT‑621 development timeline: Management outlined plans to report Phase IIb data for KT‑621 in 2027 — important for medium‑term value creation, but not an immediate catalyst. KT‑621 Phase IIb timeline
• Neutral Sentiment: Earnings call transcript available — management commentary and Q&A provide color on spend, partnering and timelines; useful for evaluating execution risk but no major surprise beyond the reported misses. Earnings call transcript
• Negative Sentiment: Q4 earnings and revenue miss — KYMR reported EPS of ($0.97) vs. consensus (~$0.77 loss) and revenue of $2.87M vs. ~$14.8M expected; revenue declined ~61% YoY. The sizable miss is the main immediate driver of the stock decline. Q4 loss and revenue miss
• Negative Sentiment: Insider selling: CEO Nello Mainolfi sold ~30,000 shares (~$2.7M), which can be perceived negatively by some investors even though holdings remain large. CEO insider sale

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. BTIG Research cut their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research note on Thursday. Barclays increased their price objective on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Finally, Mizuho lifted their target price on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $117.60.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.